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Abstract Teriparatide (TPTD) is the only currently available
therapeutic agent that increases the formation of new bone
tissue and can provide some remediation of the architectural
defects in the osteoporotic skeleton. The use of teriparatide
clinically is limited to 24 months. We review clinical findings
during daily teriparatide treatment over time. Teriparatide ap-
pears to increase bone formation more than bone resorption as
determined biochemically and histologically. Teriparatide ex-
erts its positive effects on bone formation in two distinct fash-
ions. The first is direct stimulation of bone formation that
occurs within active remodeling sites (remodeling-based
bone formation) and on surfaces of bone previously inactive
(modeling-based bone formation). The second is an increase
in the initiation of new remodeling sites. Both processes con-
tribute to the final increase in bone density observed by non-
invasive tools such as DXA. Remodeling is the repair process
bywhich skeletal tissue is maintained in a young healthy state,
and when stimulated by TPTD is associated with a positive
bone balance within each remodeling cavity. It seems likely
therefore that this component will contribute to the anti-
fracture efficacy of TPTD. Teriparatide reduces the risk of
fracture, and this effect appears to increase with longer
duration of therapy. The use of novel treatment regimens,
including shorter courses, should be held in abeyance until
controlled clinical trials are completed to define the relative
fracture benefits of such approaches in comparison to the 24-
month daily use of the agent.
Summary In patients with osteoporosis at high risk for frac-
ture, the full continuous 24-month course with teriparatide
results in improved skeletal health and outcomes than shorter
time periods.
Keywords Bone histomorphometry . Fracture .
Osteoporosis . Teriparatide
Introduction
In post-menopausal women, osteoporosis is the result of ex-
cessive bone resorption not accompanied by equally increased
bone formation. Namely, targeted remodeling removes a vol-
ume of bone which is not fully compensated. The resulting
volume deficit increases strain in neighboring bone [1].
Accordingly, pharmacologic treatment of this disease has fo-
cused on either reducing bone resorption or increasing bone
formation. Various anti-resorptive treatments for osteoporosis
are available, while teriparatide (TPTD) (recombinant human
parathyroid hormone, rhPTH) [1–34] is the first approved
anabolic agent that stimulates osteoblastic bone formation to
improve bone quality and bone mass [2]. Depending on ge-
ography, teriparatide has been approved to treat post-
menopausal women with osteoporosis, men with
hypogonadal or idiopathic osteoporosis, and men and women
with glucocorticoid-induced osteoporosis who are at high risk
for fracture [3].
In the teriparatide phase 3 Fracture Prevention Trial [4], the
planned duration of treatment with teriparatide versus placebo
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was 36 months, but the study was stopped early because of rat
toxicology findings of osteosarcoma [5, 6]. Thus, the Fracture
Prevention Trial analyzed the effects of a median 19months of
teriparatide versus placebo and the maximum duration of
teriparatide treatment was 24 months [4]. As a consequence,
the approved lifetime duration of treatment with teriparatide is
24 months [3]. Because teriparatide is approved in patients at
high risk for fracture who are generally of increased clinical
concern, the correct use of teriparatide may be important to
achieve optimal outcomes. There are considerations that
might suggest a shorter course, including the cost of the med-
ication, the requirement for daily subcutaneous injections, and
a perceived lack of certainty about whether a longer course
might confer greater benefits than a shorter course.
Because there is some uncertainty about how long patients
should be treated with teriparatide to achieve the best out-
comes, we were motivated to review the available information
regarding continuous therapy with teriparatide for 24 months.
We reviewed the effect of teriparatide on biochemical markers
of bone turnover. Also, we reviewed the long-term effects of
teriparatide on human bone tissue, including the ability to
stimulate the overfilling of resorption sites, an important effect
in the setting of high bone resorption. Furthermore, we
reviewed bone imaging techniques indicating continuous
bone formation effects and increasing bone mass during con-
tinuous teriparatide treatment. Additionally, we reviewed the
clinical data on fracture outcomes during the 24-month treat-
ment course. Finally, we reviewed the long-term safety infor-
mation for teriparatide.
Methods
The authors identified references through literature searches
using the search word teriparatide along with knowledge of
the field and continuous monitoring of the teriparatide litera-
ture during the past 20 years. On October 15, 2015, a search of
Pubmed with the terms teriparatide and B24 months^ revealed
62 references, and a search with teriparatide and B2 years^
revealed 38 references. All of the relevant references from
these searches are included in this review. Additionally, some
previously unpublished information and images are provided
as indicated.
Biochemical markers of bone turnover
Biochemical markers of bone turnover have been studied in
many teriparatide clinical trials. The reference standard of bio-
chemical marker of bone formation is procollagen type I N-
terminal propeptide (PINP) [7, 8], and the effects of
teriparatide on this marker have recently been reviewed [9].
Serum C-terminal cross-linking telopeptide of type I collagen
(βCTXI [CTX]) is considered the reference standard for bone
resorption [7].
During the first months of teriparatide treatment, there is a
rapid rise in biochemical markers of bone formation,
reflecting stimulation of osteoid formation by bone multicel-
lular units (BMUs) in their formation phase, direct modeling-
based bone formation, or both, without an accompanying in-
crease in bone resorption, so bone formation exceeds bone
resorption by a large margin early during the treatment course
[10, 11]. Subsequently, serum levels of PINP and CTX peak
after 6–12 months of TPTD therapy, followed by a gradual
decrease in both processes [12–16].
Although most studies of teriparatide have measured bio-
chemical markers of bone turnover for less than 24 months,
some studies have included measurements of biochemical
markers of bone turnover during a full 24-month treatment
course. For example, in a study of post-menopausal women
with osteoporosis, increases in PINP exceeded increases in
CTX during the entire 24-month treatment course, both in
women previously treated with alendronate and in women
who were osteoporosis drug naïve (Fig. 1) [15]. In another
study of post-menopausal women treated with teriparatide
for 24 months, the increase in bone formation markers PINP
and osteocalcin exceeded the increase in CTX throughout the
24-month treatment course [16, 17]. Most compellingly, in a
study of patients with glucocorticoid-induced osteoporosis,
increases in biochemical markers of bone formation exceeded
those of resorption during a full 36 months of treatment [14].
Thus, available clinical trial data shows that bone formation
exceeds bone resorption during the full 24 months of
teriparatide treatment. Another interpretation of these data is
that the anabolic effect of teriparatide is maximal early during
treatment when formation is increased and resorption is not.
However, if teriparatide results in overfilling of resorption
sites, then ongoing teriparatide even in the setting of high
levels of bone resorption will result not only in replacement
of old bone with a similar amount of new healthy bone but
will result in ongoing anabolism [18].
We are not aware of any published evidence that bone
turnover markers are useful for determining the duration that
individual patients should be treated with teriparatide, and for
this purpose, markers have several limitations. Among other
factors, the concentrations of markers result from the whole
skeleton amount of bone formed and resorbed, the amount of
the marker accessing the circulation, and the clearance of the
marker from the circulation [19]. Given that multiple factors
are involved in determining the concentration of each marker,
it is difficult to compare changes in different markers and
reach definitive information regarding the balance of forma-
tion to resorption. Additionally, biochemical markers of bone
turnover do not provide detailed information regarding partic-
ular skeletal site [20] or bone compartments or at individual
bone formation units. Thus, if the effects of teriparatide over
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time differ in different compartments of the skeleton, the more
general and global information from markers may miss this
information. Dynamic bone histomorphometry parameters
such as percent of mineralization surface/bone surface (MS/
BS%) correlates with serum PINP during teriparatide treat-
ment [15, 21, 22], and both PINP and the histologically ob-
tained data reviewed below suggest a continuous effect of
teriparatide both on trabecular and cortical bone new bone
formation, even later during treatment.
Bone histomorphometry
Anabolic therapy would be expected to involve bone forma-
tion exceeding bone resorption in all bone envelopes, leading
to accrual of bone and an increase in bone mass. Here, we
review the effects of 24 months of teriparatide on
histomorphometric variables in trabecular and cortical bone.
The most important study included 29 alendronate-pre-
treated and 16 treatment-naïve post-menopausal women who
were treated with teriparatide and underwent an iliac crest bi-
opsy at baseline and after 24 months of teriparatide [15, 23].
This study is highlighted because it included baseline and 24-
month biopsies with no gap between teriparatide treatment and
the biopsy procedure. An array of histomorphometry parame-
ters were collected, but we focus on mineralizing surface (MS/
BS%), a measure of the proportion of bone surface on which
new mineralized bone is being deposited (at the time of tetra-
cycline labeling) as the primary bone formation parameter
[24]. MS/BS directly measured is used in the calculation of a
number of derived indices such as bone formation rate (BFR)
[25] and is sensitive to drug effects [22]. In this study, with
pooling of the treatment groups, the increase in bone formation
from baseline to 24 months was statistically significant in all
compartments except for intracortical (Fig. 2). Also, the point
estimates of MS/BS increased from baseline in the cancellous,
endocortical, intracortical, and periosteal surface in the drug-
naïve and alendronate pre-treated patients, with statistically
significant results at the periosteal surfaces (Fig. 2) [15, 23].
These findings suggest an ongoing effect of teriparatide at
24 months to increase bone formation. The highest MS/BS%
values after 24 months were observed on the endocortical sur-
faces as compared with baseline. However, larger MS/BS%
values were observed after 1 month [26] and after 6 month of
teriparatide treatment [22], which is in agreement with the
dynamics of serum PINP values (Fig. 1).
Increased remodeling of the cortex during teriparatide treat-
ment is reflected by an increased cortical porosity and in-
creased intracortical (MS/BS%; Fig. 2). The presence of on-
going increases in intracortical remodeling after 2 years of
TPTD treatment indicates a persistent teriparatide effect dur-
ing the full treatment course. Importantly, the cortical voids
(pores) formed during teriparatide treatment show tetracycline
double labels. Although cortical voids represent a weak area
in the bone, these voids due to remodeling are transient, rep-
resent a small percentage of the cortical section area, and are
mainly located at the endocortical level; overfilling of these
voids may result in an increase in cortical bone mass, and
cortical remodeling results in the replacement of older and
potentially damaged bone with new bone [27].
Direct evidence supporting long-term modeling-based
bone formation by TPTD was provided by studies of perios-
teal bone apposition. The periosteum contains progenitor cells
capable of generating new bone in response to mechanical
stimuli [28–30]. Thus, the increase in MS/BS at 24 months
suggests an increase in periosteal modeling or the formation of
new bone uncoupled from previous resorption.Modeling adds
new bone to the bone surface and is an efficient means to
increase bone mass, but old bone is not removed and remains
beneath the newly formed bone. In studies of 1-month and of
12 to 24-month durations, teriparatide has also been shown to
induce modeling in both the trabecular and endocortical enve-
lopes [26, 31, 32].
Fig. 1 Changes in biochemical markers of bone turnover in patients
treated with teriparatide. Solid lines indicate treatment-naïve patients
(n = 16), and dotted lines indicate alendronate-pre-treated patients
(n = 29). X axes have been scaled to allow comparisons of relative
changes to reference ranges. *p < 0.05 versus from baseline, †p < 0.05
between groups. PINP procollagen I N-terminal propeptide, CTX type 1
collagen cross-linked C-telopeptide. Reproduced with permission from
Stepan JJ et al. [15]
Osteoporos Int (2016) 27:2395–2410 2397
In histomorphometry studies, double labels overlying an
eroded (scalloped) cement line are considered to represent
remodeling-based formation (bone formation on a previously
resorbed bone surface) [33]. During teriparatide treatment, the
stimulation of remodeling with overfilling of resorption sites
may be the predominant effect of teriparatide both after
1 month and after 12 to 24 months of treatment [31, 32].
This effect involves the removal of old bone and
overreplacement with new bone. The positive balance of for-
mation to resorption increases bonemass, and the replacement
of old and damaged bone with new organic matrix may result
in improved bone microarchitecture, reduced microcrack ac-
cumulation [27, 34], and improved quality and elasticity of
bone organic matrix. Indeed, bone collagen maturation mea-
sured as the ratio between α-CTX and β-CTX showed that
teriparatide treatment induced a collagen profile consistent
with young matrix [13, 35]. Patients administered teriparatide
exhibited significantly lower matrix mineralization, mineral
crystallinity, and collagen cross-link ratio when compared
with placebo, indicating that the bone-forming effect of
TPTD results in reduced bone age [36, 37]. Thus, while the
removal of old bone could transiently result in focal weakness,
the overfilling of resorption sites results in an increase in bone
mass and replacement of old bone with new bone. That
teriparatide results in overfilling of resorption sites suggests
that teriparatide should be continued rather than discontinued
in the setting of increased bone resorption to increase bone
mass and quality. Figure 3 illustrates both modeling- and
remodeling-based bone formation in a patient treated with
teriparatide.
Increased bone formation would be anticipated to increase
cortical and trabecular bone mass. Indeed, both cortical
thickness and trabecular bone volume/total bone volume in-
creased in the 24-month paired biopsy study (Fig. 4).
Increases in these parameters have been reported in other stud-
ies as well [38].
Effects of full course of teriparatide on areal bone mineral
density using dual-energy X-ray absorptiometry
The majority of the larger clinical trials after the introduction
of recombinant teriparatide (hPTH (1-34); DNA origin), in-
cluding the pivotal, phase 3 trial [4], were of approximately
18-month duration. However, more recent studies have ana-
lyzed the effects of the full 24-month treatment course.
Accordingly, this section will focus on trials including
teriparatide at the approved dose of 20 μg/day for 24 months,
and the results of those studies are provided in Table 1. Other
studies including an open-label clinical trial with synthetic
teriparatide ∼25 μg/day in combination with estrogen replace-
ment therapy for 3 years [43, 44] and studies in men and post-
menopausal women with low bone mineral density (BMD)
treated with synthetic teriparatide at a daily dose of approxi-
mately 37 μg/day for 24 months [45, 46] have also been pub-
lished but will not be reviewed here.
In the European Forsteo® Study (EuroFORS) in patients
who were either naïve to osteoporosis drugs or previously
treated with different anti-resorptive (AR) drugs, 503 post-
menopausal women with osteoporosis received teriparatide
for 24 months, including 84 subjects (16.7 %) who were
osteoporosis treatment naïve [39]. The change in lumbar
spine BMD from baseline to 24 months was +10.5 %. At
this site, the increases were +13.1 % in the osteoporosis
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Fig. 2 Bone formation in post-menopausal women with osteoporosis
treated with teriparatide as reflected by mineralizing surface divided by
bone surface (MS/BS%) at cancellous, endocortical, intracortical, and
periosteal compartments. The study included 29 patients previously
treated with alendronate and 16 patients naive to previous osteoporosis
treatment. Results are means ± SEM shown for each group and for the
two groups pooled together (the latter previously unpublished). P values
are for comparisons of baseline versus the 24-month treatment period.
The data is from the study published by Stepan et al. [15] and Ma et al.
[23]
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previously AR-treated patients, with the difference be-
tween naïve and pre-treated being statistically significant.
The change in femoral neck BMD from baseline to
24 months was, on average, +3.9 % for all teriparatide-
treated patients, and +4.8 %, and between +3.4 and
+3.9 % for the treatment-naïve and the AR pre-treated sub-
groups, respectively. Similar results were observed at the
total hip (Table 1). Most relevantly, the BMD values
showed a statistically significant increase between 18 and
24 months of daily teriparatide treatment at the spine and
the proximal femur. Indeed, in the AR-pre-treated subjects,
the BMD increment between 18 and 24 months at the hip
and femoral neck was approximately the same as the in-
crement from the first 18 months of therapy. These results
highlight the importance of the full course of teriparatide
treatment to increase cortical bone BMD, especially in sub-
jects who previously were treated long term with AR [39,
47–49].
The effect of different types of AR on the BMD response
after 24 month of continuous teriparatide treatment was also
analyzed in the EuroFORS cohort [50]. The skeletal responses
at the lumbar spine were similar among previous AR therapy
groups at each time point during the study, although previous
users of etidronate showed a higher increase, probably
reflecting its weaker anti-remodeling activity (Fig. 5).
The BMD effects after 24 months of treatment with
teriparatide 20 μg daily were also analyzed in 66 patients
who were either treatment-naïve (n=28) or had lower bone
turnover initially due to previous alendronate therapy (n=38)
in the Prague-Graz study [15]. After 24 months of treatment
with teriparatide, lumbar spine and femoral neck BMD values
increased significantly in both patient groups. Similar to the
results in the EuroFORS trial, the increase in spine BMD in
treatment-naïve subjects was statistically higher (+10.0 %)
than in alendronate prior-treated patients (+6.5 %). The in-
crease in femoral neck BMD was not different between the
two groups (+5.0 and +3.3 %, respectively; p < 0.05 vs
baseline).
A 24-month duration study of teriparatide treatment in
Asian subjects was reported by Miyauchi et al. [40]. Daily
injections of 20 μg of teriparatide in 96 Japanese men and
women with low bone mass revealed significant increases
from baseline in areal BMD at the spine (+13.42 %), total
hip (+3.67 %), and femoral neck (+3.26 %) [40].
Fig. 3 This figure shows previously unpublished iliac crest bone biopsy
specimens from a patient treated with teriparatide 20 mcg/day to illustrate
two fundamental anabolic actions: a unstained fluorescence light image
and b transmitted light for toluidine blue staining image specific for
cement lines. Newly formed lamellar bone is indicated by the yellow
arrows. Smooth cement lines and parallel collagen fiber orientation
versus the adjacent bone tissue, without interruption, indicate that this
bone formation is related to bone modeling or the deposition of new
bone on a previously quiescent bone surface. c Unstained fluorescence
light image and d transmitted light for toluidine blue staining image
specific for cement lines. Scalloped cement line shown by red arrows
represents previous resorption surface, and the smooth cement line in the
adjacent bone illustrated by yellow arrows illustrates the spilling of new
bone formation onto an adjacent surface. The mixture of scalloped
cement lines transitioning to smooth cement lines is indicative of
overfilling of a remodeling site onto the adjacent bone surface. These
previously unpublished images from the study described by Ma et al.
[32] are courtesy of Dr. Linda Ma
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The comparative effects of 24-month treatment with
teriparatide, denosumab, and the combination of the two drugs
have been recently reported [17]. In this open-label trial in 83
post-menopausal women with osteoporosis, the areal BMD
increases observed in the teriparatide-only arm were +9.5,
+2.8, and +2.0 % at the spine, femoral neck, and total hip,
respectively. Of note, 13 of the 31 patients (42 %) in the
teriparatide arm had received prior bisphosphonate treatment
for a mean of 40 months [17]. The decrease in the distal radius
BMD in the teriparatide group (−1.7 %) was not statistically
significant compared to baseline but differed from the changes
observed with denosumab (+2.1 %) or the combination group
(+2.2 %).
Cosman et al. [41] have compared the effects of daily
teriparatide for 24 months or four 3-month teriparatide cycles,
each followed by 3 months off (12-month total teriparatide) in
two groups of subjects. In osteoporosis treatment-naïve pa-
tients (n=86), increases in BMDwere twofold greater in daily




















































Fig. 4 Increase in cancellous bone volume divided by total volume and
cortical thickness from baseline through 24 months of teriparatide
treatment and included patients previously treated with alendronate and
patients naïve to previous osteoporosis treatment. Results are means
± SEM shown for each group and for the two groups pooled together
(the latter previously unpublished). P values are for comparisons of
baseline versus the 24-month treatment period. Results are from Stepan
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vs +2.1 %, and femoral neck +2.9 vs 1.2 %; p<0.05), but
radius BMD declined more in the daily therapy group (−4.2
vs −2.1 %; p = 0.08). In alendronate-pre-treated women
(n=64, average therapy duration 5.9 years), there were no
group differences ([daily vs cyclic teriparatide] spine +7.5 vs
+6.0 %, total hip +3.0 vs 2.5 %, femoral neck +3.0 vs 1.5 %,
and radius −0.7 vs −1.4 %).
In subjects with glucocorticoid-induced osteoporosis, Saag
et al. [14] have reported the BMD results of continuous treat-
ment for 36 months with teriparatide in a double-blind, com-
parative trial with alendronate (Table 1). Within the
teriparatide group, the mean percent changes in BMD were
significantly increased between 24 and 36 months at the lum-
bar spine (+9.76 vs +10.95 %; p<0.01) and at the femoral
neck (+4.76 vs +6.34 %; p<0.001) but not at the total hip
(+4.75 vs 5.22 %; p=0.115).
Finally, Cohen et al. [42] have reported 24-month areal
BMD results in a series of 21 osteoporosis treatment-naïve
pre-menopausal women with unexplained fragility fractures
or low BMD, treated with teriparatide. At 24 months, the
largest increase in BMD was at the lumbar spine (+10.8 %).
Significant increases also occurred at the femoral neck
(+7.6 %) and the total hip (+6.2 %; all p<0.001). Similar to
the results of the EuroFORS trial, the 24-month increases in
BMD at the proximal femur were approximately twice that
seen after the initial 18 months of therapy.
The BMD effectiveness of daily teriparatide in the context
of regular clinical practice has been reported in two single-
center, prospective, observational studies. In 60 women with
osteoporosis who completed a 24-month treatment course, the
BMD changes compared to baseline at the lumbar spine, total
hip, and distal radius were +10.9, +3.9, and −2.4 % (all
p<0.05) [51]. In a Scottish cohort of 217 severe osteoporotic
patients treated for approximately 21 months, the increases in
lumbar spine and femoral BMD were +13.7 and +2.3 %, re-
spectively [52]. Prior use of osteoporosis drugs, mainly oral
bisphosphonates, was reported in 85 and 56 % of the subjects
included in these two studies, respectively [51]. Finally, a
retrospective analysis of 65 women who received teriparatide
during a mean of 23 months as part of their routine osteopo-
rosis management showed a +7.6 % BMD increase at the
spine and a +4.3 % increase in the trabecular bone score
(TBS), a novel technique based on areal DXA technology that
can be used for the non-invasive assessment of intravertebral
trabecular bone microarchitecture [53]. Of note, 95 % of these
patients had prior therapy with an oral or IV bisphosphonate.
In general, BMD results of these real-world studies were sim-
ilar to those observed in randomized controlled trials.
Long-term effects of teriparatide on volumetric BMD
using quantitative computed tomography, including finite
element analysis and strength
The changes in bone distribution, geometry, and bone strength
based on 3D quantitative computed tomography (QCT) of the
femoral neck in a group of 52 subjects with osteoporosis re-
ceiving 24-month continuous teriparatide (44 of them having
received previous AR therapies) have been reported [54].
After 24 months of treatment, areal and volumetric femoral
neck BMD increased significantly by +4.0 and +3.0 %, re-
spectively, compared with baseline. Cortical cross-sectional
area (CSA) increased by +4.3 %, whereas total CSA remained
unchanged over the study duration, indicating that endosteal
but not periosteal apposition was detectable with this tech-
nique. Hip QCT revealed different temporal response patterns
Fig. 5 Adjusted mean BMD changes from baseline after 24 months of
continuous teriparatide treatment stratified by previous predominant
treatment. Numbers at top vertical bars indicate percent change from
baseline. a Lumbar spine, p < 0.001 for all within-treatment group
changes from baseline at all time points. Between-group comparisons at
6, 12, 18, and 24 months, p < 0.05 etidronate (ETI) versus alendronate
(ALN) and ETI versus risedronate (RIS) and p< 0.05 ETI versus non-
bisphosphonate (NONBP) at 18 and 24 months. All other between-group
comparisons were not statistically significant. b Femoral neck, p< 0.05
for ALN versus ETI between-group comparison at 18 months. All other
between-group comparisons were not statistically significant. Error bars
indicate SEM. *p < 0.001 for within-treatment group change from
baseline, †p < 0.05 within-treatment group change from baseline.
Reproduced with permission from Boonen et al. [50]
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of cortical and trabecular bone envelopes that cannot be sep-
arated by DXA. At 6 months of treatment, cortical volumetric
BMD (vBMD) decreased significantly, whereas trabecular
vBMD showed a significant increase. This led to a significant
decrease in total vBMD of −1.4 % (p<0.05). However, in the
remaining 18 months, cortical vBMD remained stable, where-
as cortical areas increased, which led to a net gain of +6.7 %
(p<0.0001) in cortical bone mineral content (BMC). These
results support the importance of continuous full-course treat-
ment with teriparatide, especially in AR pre-treated subjects.
Strength parameters for buckling did not change at 6 or
12 months but improved significantly at 24 months
(−4.3 %), indicating an improvement in cortical stability
[54]. Although minimal and maximal section moduli of the
femoral neck showed a non-statistically significant increase
compared to baseline at 24 months (+2.3 and +1.9 %, respec-
tively; p<0.1), it was noted that the changes in the second
year of continuous teriparatide treatment, buckling strength,
and bending strength indices increased significantly compared
to 12 months (buckling ratio −4.6 %, p<0.0001; Zmin +2.7 %,
p<0.05; Zmax +3.9 %, p<0.01).
Using a novel CT image processing technique on 65 wom-
en with baseline and 24-month paired hip scans from the
EuroFORS cohort, Poole et al. [55] showed that teriparatide
treatment increased cortical thickening. This increase was
higher at sites of hip mechanical loading including the
infero-medial cortex and the calcar femorale regions, reaching
significant increases of +6 to +8 % compared to baseline
(p<0.05). These results suggest a possible synergistic effect
between habitual loading and teriparatide in the human prox-
imal femur, since peak effects were seen at sites that are
stressed by walking. No regions of cortical thinning were
apparent.
Another study has applied high-resolution QCT and finite
element (FE) analysis at the 12th thoracic vertebra to evaluate
the effects of 24 months of continuous treatment with
teriparatide in a subset of 44 patients of the EuroFORS trial,
most of them pre-treated withAR drugs [56]. After 24months,
bone strength was increased in compression by +28.1 %, in
bending by +28.3 %, whereas the apparent bone volume frac-
tion (BV/TV) was increased by +54.7 %, volumetric BMD by
+19.1 %, and areal BMD of L1–L4 by +10.2 %. This analysis
included standardized changes to compare the performance of
the different densitometry and strength variables. Results after
24 months of treatment showed that the standardized changes
were similar for volumetric and areal BMD (+0.56 and +0.70
standard deviation increases compared to baseline, respective-
ly). Interestingly, the standardized increases in variables of the
compression test simulation were statistically larger than those
of both the densitometry measures (ranging between +1.07
and 1.18 SD compared to baseline). However, the largest
standardized increase was for the trabecular BV/TV, a surro-
gate marker of bone tissue quantity, which showed a +1.27
standard deviation increase after 24 months of treatment. The
increase in bone mass in a patient with a robust response to
teriparatide is shown over time in Fig. 6.
The FE analysis technique also allowed evaluating the
damage distribution within the vertebral body after applying
different forces. The analysis of the areas with higher damage
risk indicated that 24 months of teriparatide treatment signif-
icantly reduced the volume of damage from a similar load
from 2.7 to 0.1 % in compression and from 2.2 to 0.02 % after
bending [56]. Interestingly, CSA of the body of the 12th tho-
racic vertebra increased by +0.7 % (5.7 mm2; p<0.001),
whereas the CSA of the spinal canal increased marginally by
+0.9 % (2.6 mm2) over 24 months (p<0.001). None of the
patients showed a trend for narrowing of the spinal canal
which could result in spinal stenosis [57].
Finally, the longest study where the effects of teriparatide
on the distal radius and tibia were analyzed using high-
resolution peripheral QCT have been reported in abstract form
from the DATA cohort [58]. Volumetric cortical BMD was
decreased by almost −4.0 % after 24 months of treatment with
teriparatide at both sites. Cortical thickness was unchanged in
this study. Similar results have been published using this tech-
nique in 18-month trial duration. In a longitudinal study using
HR-pQCT in 11 post-menopausal women, treatment with
teriparatide decreased cortical vBMD at distal radius
(−4.5 %; p< 0.1) and tibia (−1.3 %; p< 0.05), whereas a
non-significant increase was seen in cortical porosity at both
sites [59]. Hansen et al. [60] performed an open-label obser-
vational study comparing effects of 18 months of treatment
with either teriparatide 20 μg/day (n=18), rhPTH(1-84), or
zoledronic acid. In response to treatment with teriparatide,
cortical vBMD at the distal radius and tibia decreased (−2.4
and −1.6 %, respectively; p<0.05) due to a significantly in-
creased cortical porosity (+32.4 and +13 %), while cortical
thickness increased at both sites (+2.0 and +3.8 %; p<0.05).
Despite these findings, these studies showed no reduction in
bone strength as assessed by FE analyses in response to
teriparatide [58–60].
The apparent decrement in radial vBMD may be a combi-
nation of several effects induced by teriparatide that occur
simultaneously, including increased endocortical remodeling,
increased remodeling space within the cortical haversian sys-
tems, and an increase in measured area due to periosteal bone
apposition [2]. Moreover, the deposits of new osteoid upon
bone surfaces actively participating in remodeling will not
attenuate photons until it is mineralized, so true cortical appo-
sition remains undetected since the mineral density is below
the threshold level that qualifies as bone [61, 62]. Since corti-
cal thickness is obtained by dividing the cortical volume by
the outer bone surface (i.e., the cortical area by the perimeter
of each slice), and the boundary between the cortical and
cancellous region is defined by a drop in mineral density,
changes in the degree of bone mineralization, particularly at
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the endocortical region—as observed with teriparatide—are
likely to affect the evaluation of cortical thickness and
BMD. Moreover, the high correlation that is normally report-
ed between cortical thickness and cortical density in HR-
pQCT studies suggest that partial volume effects limit the
reliability of cortical density measurements [63]. Another lim-
itation of this technology to assess the effects of teriparatide on
cortical bone is the issue of repositioning of the scanning
region in longitudinal studies. The HR-pQCT software incor-
porates a CSA registration method to correct axial misplace-
ment between successive scans, but possible tilt of the limb
with even small angular deviations or changes induced by
therapy on the CSA could lead to considerable mismatch in
the selected region [64].
Teriparatide fracture data
The Fracture Prevention Trial (FPT) was the pivotal phase 3
fracture trial for teriparatide. This was a randomized, double-
blind, placebo-controlled study of 1637 post-menopausal
women with prior fractures treated with daily subcutaneous
teriparatide 20 or 40 μg or placebo [4]. The median duration
of treatment was 19 months, and the median duration of ob-
servation was 21 months. Patients received daily supplements
of calcium 1000 mg and vitamin D 400 to 1200 IU.
Vertebral fracture
Lateral spine radiographs were obtained at baseline and at
study end point [4]. The first report of teriparatide efficacy
from the Fracture Prevention Trial defined vertebral fractures
by a single visual semiquantitative (SQ) reading. Readers
were blinded to group assignment but not to order of the
radiographs. By this method, a total of 64 out of 448 patients
(14 %) in the placebo group had new vertebral fractures (22
mild and 42moderate/severe) and 22 out of 444 patients (5%)
in the 20-μg/day group had new vertebral fractures (18 mild
and 4 moderate/severe). The overall relative risk reduction in
the teriparatide 20-μg/day group was 65 % and the absolute
risk reduction was 9 %.
After stopping study drug in the FPT, 1262 patients were
enrolled in a follow-up study and lateral spine radiographs
were repeated 18 months later. During this follow-up study,
other osteoporosis drugs were used by more patients in the
former placebo group than the former teriparatide group
(p=0.04). Even so, the reduction in vertebral fracture risk
associated with previous treatment with teriparatide 20 μg/
day was 41 % (p=0.004) during the follow-up study. The
absolute risk reduction from the FPT baseline to the 18-
month follow-up was 13 % [65]. Thus, the difference in ver-
tebral fracture incidence between the teriparatide and placebo
groups increased further after study drug was discontinued.
The method used to define vertebral fractures in many os-
teoporosis trials has been a quantitative morphometry method
requiring quantitative decreases in vertebral height plus confir-
mation of fracture by the semiquantitative visual methodology.
Lateral spine radiographs from the FPT teriparatide 20 μg/day
and placebo groups were re-assessed in blinded fashion using
this methodology, revealing that a total of 51 out of 448
(11.4 %) patients in the placebo group had new vertebral frac-
tures compared to 8 out of 444 (1.8 %) in the teriparatide
20-μg/day group. By this stricter fracture assessment method-
ology, the relative risk reduction in the teriparatide 20-μg/day
group was 84 % and the absolute risk reduction was 9.6 %.
Baseline 6 Months 12 Months 24 Months
App. BV/TV 0.125 0.152 0.235 0.278
∆ App. BV/TV 
vs baseline 21% 88% 123%
vBMD (mg/cm3) 44.29 54.12 87.30 105.71
---
Images are reproduced with the kind permission of Profs. Claus C. Glüer and Christian Graeff, 
Clinic of Diagnostic Radiology, Medical Physics, University SH Kiel, Germany 
Fig. 6 Rectangular Bvirtual
biopsies^ taken using
high-resolution CT scan images
of the 12th thoracic vertebra at
baseline and after 6, 12, and
24 months of treatment with
teriparatide show a progressive
increase in bone mass. These
previously unpublished images
kindly provided by Professors
Claus C. Glüer and Christian
Graeff, University SH Kiel,
Germany, are from the study
described by Graeff et al. [56]
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In the placebo group of the Fracture Prevention Trial, by
either the SQ methodology or the QM with SQ confirmation
methodology, the number and severity of prevalent vertebral
fractures at baseline were significantly predictive of the risk
for incident vertebral fractures (p<0.001) [66, 67], a phenom-
enon termed a Bfracture cascade.^ The absolute vertebral frac-
ture benefit of teriparatide may be greatest in patients with
higher burdens of vertebral fracture. For example, among pa-
tients with two prevalent vertebral fractures, 15/84 (17.9 %) in
the placebo group and 1/85 (1.2 %) in the teriparatide group
had incident vertebral fractures, representing a relative risk
reduction of 93 % (p<0.001) and an absolute risk reduction
of 17 %. Among those with three or more prevalent vertebral
fractures, 24/69 (34.8 %) in the placebo group and three of 60
(5.0 %) in the teriparatide group had incident vertebral frac-
tures, representing a relative risk reduction of 86% (p<0.001)
and an absolute risk reduction of 30 % [66]. In patients with
baseline severe vertebral fractures, new vertebral fractures
were reported for 27.7 % of the placebo group and 1.2 % of
the teriparatide group, representing a relative risk reduction of
96% (p<0.001) and an absolute risk reduction of 27%. These
results indicate that anabolic therapy with teriparatide alters
the natural history of the progression of osteoporosis.
In a post hoc analysis of the Fracture Prevention Trial, there
were approximately half as many clinical vertebral fractures in
the teriparatide 20 μg/day versus placebo group during the
first 7 months of observation; during subsequent intervals,
the incidence of clinical vertebral fractures increased further
in the placebo group but was very low in the teriparatide group
(Table 2) [68]. Thus, during additional intervals of observa-
tion, increasingly large differences in fracture incidence were
observed between the teriparatide and placebo group. These
results suggest that greater duration of treatment appeared to
be associated with greater reduction in the incidence clinical
vertebral fractures.
Non-vertebral fracture
In the Fracture Prevention Trial, non-vertebral fractures were
confirmed by a review of a radiograph or radiology report. For
the pre-specified non-vertebral fracture end point, pathologi-
cal and traumatic fractures and fractures of the face, skull,
metacarpals, fingers, and toes were excluded [4]. In the place-
bo group, non-vertebral fractures were observed for 30 of 544
patients (5.5 %) and for 14 of 541 (2.6 %) teriparatide 20 μg/
day patients. Treatment with teriparatide 20 μg/day reduced
the risk of non-vertebral fractures by 53 % compared with
placebo after a median treatment of 19 months (p=0.02).
In the Fracture Prevention Trial, placebo-treated patients
with zero, one, or two or more prior non-vertebral fractures,
the incidence of non-vertebral fractures were 4, 8, and 18 %,
respectively (Cochran-Armitage trend test, p<0.001), illus-
trating a non-vertebral fracture cascade. In the teriparatide
20-μg/day group, new non-vertebral fractures occurred in
2.7, 0, and 3.9 % of patients with zero, one, and two or more
prior non-vertebral fragility fractures, respectively (Cochran-
Armitage trend test, p=0.96). Thus, in the teriparatide group,
there was no significant increase in non-vertebral fracture risk
with increasing number of prior non-vertebral fractures, indi-
cating that teriparatide favorably impacted the natural history
of osteoporosis progression [67].
Non-vertebral fractures at specific sites in the teriparatide
20-μg/day group (n=541) versus placebo group (n=544) in-
cluded 1 versus 4 hip, 2 versus 7 wrist, 1 versus 3 ankle, 2
versus 2 humerus, 3 versus 5 rib, 0 versus 1 foot, 0 versus 3
pelvis, and 6 versus 8 other [4]. Although the trial was not
powered for detecting significant differences at individual
fracture sites, this pattern suggests that teriparatide might have
a consistent effect across different skeletal sites.
Additional analyses from the Fracture Prevention Trial
have shown the effects of teriparatide on various non-
vertebral fracture end points with inclusion or exclusion of
traumatic fractures; results showed greater relative risk reduc-
tions in the teriparatide group for non-vertebral fracture end
points most likely to be of osteoporotic origin [73]. For exam-
ple, for any non-vertebral fracture including those classified
by investigators as traumatic, the relative risk reduction in the
teriparatide 20 μg/day versus placebo group was 35%. On the
other hand, for major non-vertebral fractures (a set of fracture
sites believed to be related to osteoporosis) and with exclusion
of traumatic fractures, the relative risk reduction was 62 %.
Thus, teriparatide appears to have greater efficacy to reduce
the incidence of osteoporotic versus traumatic fractures.
Inspection of the Kaplan-Meier curve for non-vertebral
fracture shows that the placebo and teriparatide 20 μg/group
diverged after approximately 9 months with the gap between
the groups subsequently increasing with longer duration of
treatment [4]. During the 30-month follow-up study after
study drugs were stopped, the gap between the placebo and
teriparatide group further increased, indicating that the skeletal
effect of teriparatide was maintained after study drug cessation
[74]. Thus, non-vertebral fragility fractures occurred in 55
cases (13.3 %) treated with placebo during the double-blind
phase and in 37 cases (8.5 %) in the former teriparatide 20 μg-
treated group. Most of the patients received any type of AR
after stopping the study medication. The relative risk reduc-
tion was 38 % (p=0.022).
The relationship between duration of teriparatide treatment
and reduction in non-vertebral fracture risk in the Fracture
Prevention Trial has been further explored [68]. Fracture inci-
dence during the first, second, and third 7 months of the study,
corresponding to approximately one thirds of the median ob-
servation, was assessed (Table 2). Patients entered each sub-
sequent observation period if they remained on study treat-
ment and had not previously fractured. During the initial
7 months of observation, the incidence of non-vertebral
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fractures was similar in the placebo and teriparatide 20-μg/day
groups. Compared to the placebo group, during the next
7 months, there were approximately half as many fractures
in the teriparatide group, and during the final 7 months, there
were about a fourth as many fractures in the teriparatide group
[68]. The risk for non-vertebral fracture in the teriparatide
20 μg/day versus placebo group over time was modeled, con-
trolling for baseline age, vertebral T-score, and multiple ver-
tebral fractures. The results showed that the relative hazard of
non-vertebral fragility fractures was reduced by 7.3% for each
additional month of teriparatide (p=0.009). Thus, the hazard
ratio after 1 month of therapy was 92.7 % of that at baseline,
after two months was 85.9 %, and after three months was
79.7 %, etc. Graphical representation of these results showed
that after 24 months of teriparatide, the predicted hazard for
non-vertebral fracture in the teriparatide versus placebo group
was approximately 20%. Thus, early during teriparatide treat-
ment, the incidence of non-vertebral fracture may not be dif-
ferent from placebo; thereafter, increased duration of
teriparatide treatment appeared to result in progressive de-
creases in non-vertebral fracture risk.
A post hoc analysis was conducted regarding an osteopo-
rotic fracture end point including pooled fractures of the spine
and low-trauma non-vertebral fractures [75]. This end point
was assessed for Fracture Prevention Trial plus the follow-up
study through 18 months, at which time patients underwent
lateral spine imaging. During the 39 total months of observa-
tion, the relative risk reduction for any fracture in the
Table 2 Teriparatide 20 μg/day fracture data from clinical trials, observational studies, and claim database studies
Reference Interval duration Fracture type Treatment Fracture rates (%)
Intervals
1 2 3 4
Clinical trial
[27, 68] 7 months Non-vertebral TPTD 1.3 % 0.83 % 0.66 %**
Placebo 1.5 % 1.8 % 2.8 %
Clinical vertebral TPTD 0.9 % 0.0 % 0.3 %
Placebo 1.8 % 2.6 % 3.1 %
Observational studies
[69] 6 months Non-vertebral (all) TPTD 1.42 % 0.91 %* 0.70 %* 0.81 %*
Non-vertebral (female) TPTD 1.49 % 0.94 %* 0.74 %* 0.90 %*
Non-vertebral (male) TPTD 0.81 % 0.66 % 0.38 % 0.0 %
[27] 6 months Hip TPTD 0.27 % 0.07 %* 0.15 % 0.0 %*
[70] 6 months Clinical fractures TPTD 4.6 % 3.5 %* 2.8 %*
Clinical vertebral TPTD 1.8 % 1.3 % 0.7 %*
Non-vertebral TPTD 2.9 % 2.2 % 2.1 %
Main non-vertebral TPTD 2.4 % 1.8 % 1.7 %*
[71] Clinical fractures TPTD 3.0 % 2.0 % 1.7 %* 1.6 %*
Clinical vertebral TPTD 1.1 % 0.1 %* 0.2 %* 0.3 %*
Non-vertebral TPTD 2.0 % 1.9 % 1.5 % 1.3 %
Claim database study Teriparatide treatment duration
<6 6–12 13–18 19–24
[72]*** 6 months Any clinical TPTD 101.1 75.9 72.5 51.5
Vertebral TPTD 24.7 13.5 1.3 6.1
Hip TPTD 10.0 8.4 6.6 5.2
Non-hip/non-vertebral TPTD 66.4 54.0 54.6 40.2
To illustrate the effect of teriparatide over time, fracture rates are shown by different intervals of observation. For example, in the Lindsay et al. analysis at
the top of the table, the fracture rates during months 0–7, 7–14, and >14 were reported and are reflected in the table as interval duration 7 months and
fracture rates are provided for intervals 1, 2, and 3. For clinical trials and observational studies, the fracture rates are percentages determined as the
number of patients with fractures among the total observed patients during the interval. For the Yu et al. [72] claim database study, patients had differing
durations of teriparatide treatment but the same overall follow-up of 24 months post-teriparatide initiation
TPTD teriparatide
*p< 0.05 versus the first interval
**The relative hazard of non-vertebral fragility fractures decreased by 7.3 % for each additional month of teriparatide 20 μg versus placebo (p= 0.009)
***Fracture incidence is shown as fractures per 1000 patient-years of observation
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teriparatide 20-μg/day group was 46 %, the absolute risk re-
duction (ARR) was 12.7 % (p<0.0001), and the number
needed to treat (NNT) to prevent a new fracture was 8.
Patients with more severe osteoporosis had greater absolute
benefit. For example, in patients with low BMD and baseline
vertebral fractures, the relative risk reduction was 56 %, ARR
was 21.7 % (p<0.0001), and NNTwas 5. Thus, for the oste-
oporotic fracture end point, teriparatide showed efficacy over
a duration including the Fracture Prevention Trial plus
18 months of follow-up and the greatest absolute benefit
was among the patients with most severe osteoporosis [75].
Observational studies
Several large observational studies of osteoporosis patients
treated with teriparatide 20 μg/day have been conducted. In
these studies, patients are treated with teriparatide as part of
their normal clinical care, and so, the patient populations are
more representative of Breal-world^ patients than those in ran-
domized controlled trials which include many inclusion and
exclusion criteria. However, these observational studies of
teriparatide have not included control groups so that fractures
in patients treated with teriparatide cannot be compared to
fractures in patients treated with other treatments. Instead,
these studies have been designed to compare fracture inci-
dence over time. The basis for this design is the finding in
the Fracture Prevention Trial described above that the inci-
dence of non-vertebral fractures in patients treated with place-
bo and teriparatide is similar during the initial approximately
9 months, so that the fracture incidence during the initial
months of teriparatide treatment provides a reference fracture
incidence which might be approximately similar to a placebo
fracture incidence. Fracture incidence later during treatment
can then be compared to fracture incidence during the refer-
ence interval.
For example, the Direct Assessment of Non-Vertebral
Fractures in Community Experience (DANCE) study evalu-
ated 4085 men and women treated with teriparatide for
24 months and then observed for another 24 months [69].
Using the same methodology as that used to examine the
effect of teriparatide over time in the Fracture Prevention
Trial, the incidence of non-vertebral fragility fracture were
1.42, 0.91, 0.70, and 0.81 % for the four 6-month teriparatide
treatment periods (Table 2). The odds of fracture during each
6 month interval were lower than the first 6-month reference
period. Compared to the reference interval, the odds of frac-
ture was 43 % lower in the last 6-month period of teriparatide
treatment. After stopping teriparatide, the incidence of fracture
during the subsequent 6-month intervals after treatment ces-
sation were 0.80, 0.68, 0.33, and 0.33 %. The results from this
study indicated that after an initial 6-month reference period,
non-vertebral fracture incidence was reduced, and this
reduction persisted after teriparatide was stopped. The inci-
dence of hip fractures showed a similar pattern over time [27].
In an observational study of 1581 European post-
menopausal women treated with teriparatide for 18 months
and then observed for another 18 months (European Forsteo
Observational Study (EFOS)), a 74 % decrease in the adjusted
odds of any incident clinical fracture in the 30- to <36-month
period compared with the first 6-month period was observed
(p<0.001) [76]. The reduction during the 12- to <18-month
active treatment period compared with the first 6 months
(Table 2) was 39 % (p=0.013). The decreases in adjusted
odds of having a non-vertebral fracture were significantly
lower during the 24- to <30-month interval (60 %; p≤0.01)
and 30- to <36-month interval (59 %; p≤ 0.01), compared
with the first 6 months of teriparatide treatment.
These results have been more recently confirmed in a 24-
month treatment observational study that included 1454 post-
menopausal and men with osteoporosis as well as patients
with glucocorticoid-induced osteoporosis (ExFOS) [71]. A
53 % decrease in the odds of low-trauma clinical fractures in
the last 18–24-month period compared with the first 6-month
period was observed (p<0.05).
Finally, in one real-world study, 3587 patients treated with
teriparatide who had data available 12 months pre- and
24 months post-teriparatide initiation were identified using
the Thomson Reuters MarketScan® database [72]. Fracture
risk decreased as teriparatide persistence increased for any
clinical, vertebral, and non-vertebral fractures (Table 2).
Similar reductions in hip fracture were observed in patients
treated longer versus shorter with teriparatide, although the
results did not reach statistical significance. Using the same
database, another group reported teriparatide outcomes for 11,
407 patients similarly treated with teriparatide and having
similar pre- and post-treatment follow-up [77]. This study
appeared to show similar results and confirmed lower risk
for fracture for persistent versus non-persistent patients [78].
Long-term safety data
In the Fracture Prevention Trial with a median treatment of
19 months and observation of up to 24 months, dizziness was
reported for 6 % of the placebo group and 9 % of the
teriparatide 20-μg/day group (p=0.05), and leg cramps were
reported for 1% of the placebo group and 3% (p=0.02) of the
teriparatide 20-μg/day group [4]. Nausea and headache were
similar in the placebo and teriparatide 20-μg/day groups.
Deaths, hospitalizations, cardiovascular disorders, urolithia-
sis, and gout were similar in the placebo and teriparatide
groups. There were no cases of osteosarcoma in the study,
and indeed, cancer was reported for 4 % of the placebo group
and 2 % of the teriparatide 20-μg/day group (p=0.02). Blood
pressure and heart rate, measured at each visit prior to
teriparatide dosing, were unaffected by teriparatide.
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Assessments of serum calciumwere increased 4 to 6 h after
dosing, and mild hypercalcemia was noted in 2 % of the pla-
cebo group and 11 % of those in the teriparatide 20-μg/day
group, although sustained hypercalcemia was uncommon and
serum calcium was usually normal 16 to 24 h post-injection
[4]. Treatment was discontinued because of persistently ele-
vated serum calcium concentrations in one woman in the pla-
cebo group and one in the teriparatide 20-μg group. Twenty-
four-hour urinary calcium excretion increased during
teriparatide treatment by approximately 30 mg (0.75 mmol)
per day, but the incidence of hypercalciuria defined as urinary
calcium excretion greater than 300 mg (7.5 mmol) per day
was not different between the placebo and teriparatide
20-μg/day groups. While serum magnesium concentrations
decreased slightly in the teriparatide 20-μg/day group, serum
uric acid concentrations increased by 13 to 20 % in the
teriparatide 20-μg/day group. The increase in serum uric acid
was not associated with increases in gout or nephrolithiasis.
After stopping study drug, the changes in laboratory parame-
ters were resolved at a follow-up visit.
The timing of adverse events in the Fracture Prevention
Trial was assessed during intervals including months 0–7, 7–
14, and >14. During months 0–7, nausea was reported for
7.58 % of the teriparatide 20-μg/day patients and 4.6 % of
the placebo patients (p<0.05). Dizziness was 4.04 % in the
placebo group and 6.65% in the teriparatide 20-μg/day group,
and leg crampswas 0.55% in the placebo group and 1.85% in
the teriparatide 20-μg/day group; these differences did not
reach statistical significance. The incidence of adverse events
was not significantly different during the subsequent time in-
tervals. These findings reveal that common adverse effects of
teriparatide, if they are to occur, appear to occur early during
treatment and that new adverse events are less likely to occur
during longer durations of treatment [68].
Safety was assessed in 503 post-menopausal women with
severe osteoporosis treated with teriparatide for 24 months in
the EuroFORS study [39]. The most frequently reported ad-
verse events were nausea (12.5 %), arthralgia (11.7 %), hy-
pertension (8.9 %), and headache (6.9%). Hypercalcemia was
reported in 5% of the patients. Similar results were reported in
the 18-month EFOS observational study; the most common
adverse events were nausea (5.5 %), headache (4.4 %), fa-
tigue, and depression (2.7 % each).
The incidence of osteosarcoma in humans aged
≥60 years is approximately 1 in 250,000 per year but is
much higher in patients with Paget’s disease, external
beam, or brachytherapy radiation treatment involving the
skeleton or open epiphyses [79]. Based on the rat toxicol-
ogy finding of osteosarcoma, the labeling for teriparatide
recommends against using the drug in patients at high risk
for osteosarcoma, including those with these risk factors.
Additionally, because of the potential for Paget’s disease,
an additional warning exists for those with an unexplained
alkaline phosphatase. This risk mitigation strategy should
reduce the incidence of osteosarcoma among patients treat-
ed with teriparatide. Even so, based on the large number of
patients treated with teriparatide worldwide, some cases of
osteosarcoma would be expected and indeed have been
reported. The first reported case occurred sometime during
the second year of Forteo treatment [79]. The second re-
ported case occurred in the pelvis of a man who had pre-
viously undergone radiation therapy for prostate cancer
[80]. This man was diagnosed with an osteosarcoma of
the pelvis 2 months after beginning teriparatide treatment.
A third case reported at a meeting appears to be have been
pre-existing since the case involved enlargement of a mass
noted prior to initiation of teriparatide [81]. To date, no
apparent connection between longer treatment with
teriparatide and osteosarcoma has been observed in
humans. Furthermore, a post-marketing surveillance study
has not observed a connection between teriparatide treat-
ment and osteosarcoma in humans [82].
Discussion
Because teriparatide is indicated for treatment of patients with
osteoporosis at high risk for fracture, patients treated with this
drug are often of high clinical concern, especially since this
drug has been approved for a total treatment duration limited
to 24 months. Accordingly, optimal use of the drug is impor-
tant to achieve the best possible outcomes. We have here
reviewed that patient outcomes appear to be improved by
the full 24-month continuous course of teriparatide. Both the
biochemical and histological data suggest ongoing bone for-
mation through 24 months, resulting in increases in bone
mass, even in patients with low bone turnover induced by
long-term previous anti-resorptive treatment. Consistent with
these observations, bone mass and strength increase and frac-
ture risk decreases during longer treatment with the drug.
There are limitations. Comparisons of the amount of bone
formed and resorbed as determined either by biochemical
markers of bone turnover or bone histomorphometry do not
provide certainty regarding the bone balance. However, the
consistency of the findings suggesting a positive bone balance
at the biochemical, histological, radiographic, and clinical out-
come levels are compelling that a positive balance of bone
formation to resorption likely exists during the full 24-month
treatment course. A clinical trial in which patients are random-
ized to different durations of teriparatide treatment has not
been performed. If such a trial were performed, it should be
designed to compare fracture outcomes.
We conclude that for patients with osteoporosis at high risk
for fracture treated with teriparatide, available information
suggests that the full 24-month treatment course is important
to achieve the best clinical outcomes.
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